All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-06-09T11:23:06.000Z

What are the challenges and possibilities of ctDNA to monitor response and relapse in MM?

Jun 9, 2021
Share:

Bookmark this article

During the 2021 ASCO Annual Meeting, the Multiple Myeloma Hub spoke with Parameswaran Hari, Medical College of Wisconsin, Milwaukee, US. We asked, What are the challenges and possibilities of circulating tumor DNA (ctDNA) to monitor response and relapse in MM?

Using ctDNA to detect minimal residual disease (MRD) in the peripheral blood presents a sensitive, noninvasive technique to predict relapse in patients with multiple myeloma (MM). Hari outlines the advantages of ctDNA analysis over bone marrow aspiration, and presents data from a study investigating the prognostic value of ctDNA in patients with MM following auto-HCT.

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox